ADL/Metabolomic Technologies' PolypDx Urine-Based Diagnostic Test

Atlantic Diagnostic Laboratories has launched Metabolomic Technologies' PolypDx, a non-invasive urine-based test for detection of adenomatous polyps, the precursor to colorectal cancer. PolypDx only requires a small urine sample for analysis. In a Canadian clinical trial the test demonstrated significantly higher sensitivity than a current fecal-based screening test to detect adenomatous polyps, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.